# A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

> **NCT05546411** · PHASE2 · TERMINATED · sponsor: **Kimberly Perez, MD** · enrollment: 8 (actual)

## Conditions studied

- Pancreatic Cancer
- Resectable Pancreatic Cancer
- Borderline Resectable Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** mFOLFIRINOX
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** NIS793
- **RADIATION:** Chemoradiation
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT05546411
- **Lead sponsor:** Kimberly Perez, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-06
- **Primary completion:** 2023-08-16
- **Final completion:** 2023-10-13
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are stopping all clinical development of NIS793 in pancreatic cancer, effective immediately.
- **Last updated:** 2024-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546411, "A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05546411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*